progesterone receptor negative breast cancer

Release time ：Dec-25,2024

Progesterone receptor-negative (PR-negative) breast cancer is a subtype of breast cancer defined by the lack of progesterone receptors on the cancer cell surface, indicating that tumor growth is unlikely to be significantly affected by progesterone. Consequently, this form of breast cancer tends to be less responsive to hormonal therapies, prompting treatment plans to emphasize alternative approaches such as chemotherapy, radiotherapy, or targeted therapies.

In crafting a treatment strategy for PR-negative breast cancer, physicians tailor the plan to the individual patient’s condition and the tumor’s specific traits. For instance, if the tumor tests positive for HER2, targeted HER2 therapies may be employed. Early-stage breast cancer patients often include surgery in their treatment regimen, which could involve either breast-conserving surgery or mastectomy. Postoperatively, adjuvant treatments like radiotherapy or chemotherapy may be necessary to minimize the risk of cancer recurrence.

For individuals with PR-negative breast cancer, it is crucial to follow a treatment plan under a physician’s supervision and adhere to their recommendations for regular check-ups. Additionally, maintaining a healthy lifestyle, including a balanced diet, regular exercise, and refraining from smoking, can contribute to better therapeutic outcomes and overall quality of life.